Classification of type 1 diabetes: A pathogenic and treatment-based classification.

AIM To improve the diagnosis and classification of patients who fail to satisfy current type 1 diabetes diagnostic criteria. METHODS Review of the literature and current diagnostic guidelines. DISCUSSION We propose a novel, clinically useful classification based on islet autoantibody status and non-fasting C-peptide levels. Notably, we discuss the subgroup of latent autoimmune diabetes in the young and propose a new subgroup classification of autoantibody negative type 1 diabetes in remission. CONCLUSION A novel classification system is proposed. Further work is needed to accurately diagnose and manage minority type 1 diabetes subgroups.

• Publication year

  2024

• Venue

  Diabetes & metabolic syndrome

• Publication date

  2024-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.dsx.2024.102986PMID 38503115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023.

  2022cited by this paper
• Latent autoimmune diabetes in youth shows greater autoimmunity than latent autoimmune diabetes in adults: Evidence from a nationwide, multicenter, cross‐sectional study

  2022cited by this paper
• Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype.

  2021cited by this paper
• The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2021cited by this paper
• Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes

  2021cited by this paper
• Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel

  2020cited by this paper
• Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors’ Expert Forum

  2020cited by this paper
• Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice

  2019cited by this paper
• Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study

  2019cited by this paper
• Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated with Older Age and Insulin Resistance.

  2019cited by this paper
• University of Birmingham Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort

  2018cited by this paper
• A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults

  2015cited by this paper
• The clinical utility of C-peptide measurement in the care of patients with diabetes

  2013cited by this paper
• Latent autoimmune diabetes in adults (LADA) should be less latent

  2005cited by this paper

• Islet autoantibodies in Thai individuals diagnosed with type 1 diabetes before 30 years of age: a large multicentre nationwide study

  2025cites this paper
• Envisioning Tools to Help Classify Type 1 Diabetes and Type 2 Diabetes in New-Onset Adult Diabetes

  2025influential citation
• Computational Spectroscopy Studies of Model Ternary Complexes of Copper(II), C-Peptide, and Serum Albumin Using Excited State-Targeted Geometry Optimization.

  2025cites this paper
• Advancing Diabetes Classification: A Comprehensive Framework Integrating Cost-Sensitive Learning, ADASYN, and Stacking Ensembles

  2025cites this paper
• Highlights of the current issue

  2024cites this paper
• Comment on Stone et al. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770-781.

  2024cites this paper